Mass spectrometry - Articles and news items

PerkinElmer Product Hub NEXION 2000 ICP/MS

Product Hub: PerkinElmer’s NexION® 2000 ICP-MS

Whitepapers / 2 May 2017 / PerkinElmer

The NexION® 2000 ICP-MS is designed to handle any sample matrix, address any interference, and detect any particle size. The system delivers enhanced matrix tolerance and low maintenance, which compresses workflows like never before, making small and high-throughput contract labs more productive in the process. A dynamic range from ppq to percent levels and a choice of modes and gases make it possible to analyse even the most difficult samples. And it comes preloaded with powerful methods that make it easy to set up and go…

Digital issue #2 in-depth focus mass spectrometry

Mass Spectrometry In-Depth Focus 2017

Issue 2 2017, Supplements, Z Homepage promo / 13 April 2017 / European Pharmaceutical Review

In this Mass Spectrometry In-Depth Focus: Mass spectrometry in the development of protein biologics; and GC-MS applications in pharmaceuticals analysis…

Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compression

Webinars, Z Homepage promo / 19 October 2016 / Viavi

In this webinar, experts from Viavi, Pfizer & Université Laval discussed how MicroNIR is used to optimise fluid bed drying and to reduce waste at tablet compression…

Application of LCMS in small-molecule drug development

Issue 4 2016 / 24 August 2016 / Chunang (Christine) Gu, David Russell and Peter Yehl, Genentech

As a technology, mass spectrometry (MS) has evolved to the point where it is used throughout the drug development process. In particular, when MS is coupled with high-performance liquid chromatography (HPLC) it adds an orthogonal detection function for sample analysis and provides unique capabilities for pharmaceutical analysis, such as sensitivity, selectivity, speed of analysis and rich mass information. This article describes the fundamentals and general applications of hyphenated LC-MS in supporting small-molecule drug development, such as impurity and degradant structural characterisation, and qualitative and quantitative analysis. In addition, some newly-developed technologies in LC and MS are discussed in terms of their future application within pharmaceutical development…

Characterising therapeutic antibodies and ADCs using mass spectrometry

Characterising therapeutic antibodies and ADCs using mass spectrometry

Issue 4 2016 / 24 August 2016 / Ioannis Papayannopoulos, Celldex Therapeutics

Since the 1970s, the advent of biotechnology has resulted in the development and commercialisation of many therapeutic proteins, including antibodies and antibody fragments, for the treatment of human diseases. Examples include antibody treatments for autoimmune diseases (for example, adalimumab [Humira®] for rheumatoid arthritis), cancers (such as trastuzumab [Herceptin®] for breast cancer), degenerative conditions (including ranibizumab [Lucentis®] for macular degeneration), viral and bacterial infections, as well as others. Additionally, antibodies are used as imaging reagents, linked to radionuclides or non-radioactive rare earth metals, and quite extensively employed as reagents in biomedical research, commercial medical tests and clinical laboratory assays (for example, enzyme-linked immunosorbent assay [ELISA])…

Biochemical Assay Development Using Novel MALDI High-Throughput Screening System

Whitepapers, Z Homepage promo / 4 August 2016 / Bruker

This work focuses on developing biochemical assays where substrate and product are small molecules using a novel MALDI-HTS system…

Mass Spectrometry In-Depth-Focus 2016

Mass Spectrometry: In-Depth Focus 2016

Issue 2 2016, Supplements, Z Homepage promo / 4 May 2016 / European Pharmaceutical Review

Featuring: Novel trends in glycosylation analysis of biotherapeutics by mass spectrometry; The use of mass spectrometry for the characterisation of proteins in small molecule drug discovery; Mass Spectrometry Q&A…

Proteomic mass spectrometry imaging for detecting malignant melanoma

Blog, Z Homepage promo / 26 April 2016 / Victoria White, Digital Content Producer

In an exclusive interview, Erin Seeley of Protea Biosciences discusses Proteomic Mass Spectrometry Imaging and Protea’s recently announced license agreement with Yale…

Application Note: MALDI-ToF Mass Spectrometry - A valid alternative for microbial identification - Wickham Labs

Application Note: MALDI-ToF Mass Spectrometry – A valid alternative for microbial identification

Whitepapers / 11 January 2016 / Wickham Laboratories Limited

MALDI-ToF mass spectrometry, a phenotypical RMM for microbial identification, is a unique, highly accurate alternative method that facilitates cost-effective, precise and rapid data acquisition…

MALDI High-Throughput Screening beyond 100,000 Samples per Day in Drug Discovery

Poster note: MALDI high-throughput screening beyond 100,000 samples per day in drug discovery

Whitepapers / 17 November 2015 / Bruker and Novartis

This work focuses on the improvement of MALDI-TOF automation parameters to further increase sample analysis speed in HTS assays to more than 100,000 samples per day…

Fit-for-purpose miniature NIR spectroscopy for solid dosage manufacturing

Webinars / 26 October 2015 /

This webinar discusses how miniaturised spectrometers facilitate testing of different control schemes with the goal of enabling real-time feedback control of continuous manufacturing processes…

Thermo Fisher Scientific

Thermo Fisher Scientific Receives IVDD CE Mark for its Thermo Scientific Prelude MD HPLC, Endura MD Mass Spectrometer and ClinQuan MD Software

Supplier news / 10 September 2015 / Thermo Fisher Scientific

Now available to clinical laboratories in Europe for general in vitro diagnostic use …


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...